Hydration effect on kidney function and serum electrolyte in children with tumor lysis syndrome (TLS) and risk of TLS.
blood urea nitrogen
creatinine serum
hyperhydration
serum electrolytes
tumor lysis syndrome
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
27
11
2020
accepted:
23
02
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
15
2
2022
Statut:
epublish
Résumé
Tumor lysis syndrome (TLS) is a life-threatening oncology emergency disorder, which may cause acute kidney injury (AKI), arrhythmias, seizures, and sudden death. Hydration is used to prevent TLS in medium-high risk patients, and treatment in TLS patients. According to the pediatric protocol in Dr. Soetomo District General and Teaching Hospital, close monitoring is required to prevent the progression of hematological malignancy towards TLS. The study aimed to analyze the hydration effect on potassium, calcium, and phosphate levels; serum creatinine (sCr); and blood urea nitrogen (BUN) level. This was an observational and prospective study conducted at Dr. Soetomo District General and Teaching Hospital for four months on 15 pediatric hemato-oncology patients who got TLS and in risk of TLS. Laboratory parameters were observed in 11 days, pre and post hydration. Among the 15 patients who met the inclusion criteria, there were eight TLS patients and seven TLS risk patients. After hydration administration 67% of TLS patients achieved normal potassium level, 75% achieved normal phosphate level, 0% achieved normal calcium level, and 50% achieved normal sCr and BUN levels. Meanwhile, TLS risk patients reached normal level in all parameters. This difference in performance is caused by disease progression. Hydration can maintain serum electrolytes and renal function in a normal range, preventing TLS in TLS risk patients. In TLS patients, hydration only tends slow the progression of the disease.
Identifiants
pubmed: 34214307
pii: jbcpp-2020-0412
doi: 10.1515/jbcpp-2020-0412
doi:
Substances chimiques
Electrolytes
0
Phosphates
0
Potassium
RWP5GA015D
Calcium
SY7Q814VUP
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-609Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Howard, S, Jones, D, Pui, C. The tumor lysis syndrome. N Engl J Med 2011;364:1844–54.https://doi.org/10.1056/nejmra0904569.
Edeani, A, Shirali, A. Tumor lysis syndrome. In: Onco-nephrology curriculum [internet]. Connecticut: American Society of Nephrology; 2016:1–8 pp.
Belay, Y, Yirdaw, K, Enawgaw, B. Tumor lysis syndrome in patients with hematological malignancies. J Oncol 2017;2017:9684909. https://doi.org/10.1155/2017/9684909.
Williams, SM, Killeen, AA. Tumor lysis syndrome. Arch Pathol Lab Med 2019;143:386–93.https://doi.org/10.5858/arpa.2017-0278-rs.
Mirrakhimov, AE. Tumor lysis syndrome: a clinical review. World J Crit Care Med 2015;4:130.https://doi.org/10.5492/wjccm.v4.i2.130.
Ñamendys-Silva, SA, Arredondo-Armenta, JM, Plata-Menchaca, EP, Guevara-García, H, García-Guillén, FJ, Rivero-Sigarroa, E, et al.. Tumor lysis syndrome in the emergency department: challenges and solutions. Open Access Emerg Med 2015;7:39–44. https://doi.org/10.2147/oaem.s73684.
Tazi, I, Nafl, H, Elhoudzi, J, Mahmal, L, Harif, M. Management of pediatric tumor lysis syndrome. Arab J Nephrol Transplant 2011;4:147–54. https://doi.org/10.4314/ajnt.v4i3.71027.
Li, HCW, Chung, OKJ, Tam, CJ, Chiu, SY. Effective prevention and management of tumor lysis syndrome in children with cancer. J Pediatr Oncol Nurs 2015.
Micho, H, Mohammed, Y, Hailu, D, Genet, S. Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC Hematol 2018;18:1–7. https://doi.org/10.1186/s12878-018-0117-0.
Al Bagshi, M, Hassan, ES, Sadek, AO, Abbas, AA. Tumor lysis syndrome in children with acute leukemia: incidence and outcome. J Appl Hematol 2013;4:100. https://doi.org/10.4103/1658-5127.123304.
Marsh, A, Agrawal, AK, Feusner, JH. Tumor lysis syndrome. In: Feusner, J Hastings, C Agrawal, A. editors. Supportive care in pediatric oncology. Pediatric oncology. Berlin, Heidelberg: Springer;2015.
Amieva-Wang, N. A practical guide to pediatric emergency medicine, 1st ed. Cambridge: Cambridge University Press; 2011:357 p.
Burns, RA, Topoz, I, Reynolds, SL. Tumor lysis syndrome: risk factors, diagnosis, and management. Pediatr Emerg Care 2014.
Naeem, B, Moorani, KN, Anjum, M, Imam, U. Tumor lysis syndrome in pediatric acute lymphoblastic leukemia at tertiary care center. Pak J Med Sci 2019;35:899–904.
Daver, N, Kantarjian, H, Marcucci, G, Pierce, S, Brandt, M, Dinardo, C, et al.. Clinical characteristics and outcomes in patients with acute promyelocytic leukemia and hyperleucocytosis. Br J Haematol 2014;168:646–53.https://doi.org/10.1111/bjh.13189.
Gong, J, Wu, B, Guo, T, Zhou, S, He, B, Hyperleukocytosis, PX. A report of five cases and review of the literature. Oncol Lett 2014;8:1825–7. https://doi.org/10.3892/ol.2014.2326.
Burghi, G, Berrutti, D, Manzanares, W. Tumor lysis syndrome in intensive therapy : diagnostic and therapeutic encare. (English Ed [Internet]. Med Intensiva 2011;35:170–8. https://doi.org/10.1016/s2173-5727(11)70022-4.
Avner, E, Yoshikawa, N, Harmon, W, Niaudet, P, Emma, F, Goldstein, S. Pediatric nephrology, 7th ed. London: Springer; 2016.
Alakel, N, Middeke, J, Schetelig, J, Bornhäuser, M. Prevention and treatment of tumor lysis syndrome , and the efficacy and role of Rasburicase. Onco Targets Ther 2017;10:597–605. https://doi.org/10.2147/ott.s103864.
Kliegman, R, Stanton, B, St. Geme, J, Schor, N, Behrman, R, Nelson, W. Nelson textbook of pediatrics, 21st ed. Philadelphia: Elsevier; 2020.
Wilson, FP, Berns, JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis [Internet] 2014;21:18–26. https://doi.org/10.1053/j.ackd.2013.07.001.
Calvo Villas, JM. Tumour lysis syndrome. Med Clin (Barc) [Internet] 2019;152:397–404. https://doi.org/10.1016/j.medcle.2019.03.006.
Sarno, J. Prevention and management of tumor lysis syndrome in adults with malignancy. J Adv Pract Oncol 2013;4:101–6.
Adeyinka, A, Bashir, K. Tumor lysis syndrome [Internet]. Treasure Island: StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518985/.
Howard, S. Tumor lysis syndrome. In: Abeloff’s clinical oncology, 6th ed. Philadelphia: Elsevier; 2020:572–80 pp.
Cairo, MS, Coiffier, B, Reiter, A, Younes, A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578–86. https://doi.org/10.1111/j.1365-2141.2010.08143.x.
Jones, G, Will, A, Jackson, G, Webb, N, Rule, S. Guidelines for the management of tumor lysis syndrome in adults and children with hematological malignancies on behalf of the British committee for standards in hematology. Br J Haematol 2015;169:661–71. https://doi.org/10.1111/bjh.13403.
Held-warmkessel, J. Preventing and managing tumor lysis syndrome. Nurse 2010;40:26–31.https://doi.org/10.1097/01.nurse.0000367861.28564.32.